Years after the biopharmaceutical industry stepped up to create COVID-19 vaccines as the virus spiraled into a global ...
For GSK’s Ramakrishnan, who has served as CDTO since 2021, the biggest challenge was helping her company get a head start in ...
GSK Plc is pushing the UK government to give pharmaceutical companies more access to its public health data troves, to ...
GSK is opening the door to a new era in urinary tract infection (UTI) treatment with its Blujepa, the first in a new class of ...
GSK said on Tuesday that it is studying a group of more than a million older adults in the UK to examine whether its ...
Pharmaceutical Technology on MSN1d
FDA approves GSK’s Blujepa for uncomplicated UTIsThe FDA has approved GSK’s Blujepa for treating uncomplicated urinary tract infections (uUTIs) in adult females and ...
Stock analysts at Zacks Research upped their FY2027 earnings per share estimates for GSK in a report issued on Tuesday, March ...
The European Medicines Agency will review GSK's request to approve its asthma drug Nucala as an additional treatment for ...
The British pharmaceutical giant is working with the U.K. Dementia Research Institute to exploit a “natural randomization” ...
GSK takes advantage of natural experiment to study whether shingles vaccine can reduce dementia risk
After multiple studies have suggested a link between its shingles vaccine and dementia prevention, GSK is taking advantage of ...
The study will analyse electronic health records of 65- and 66-year olds from the UK’s National Health Service (NHS).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results